Skip to content

Isonicotinic Acid Hydrazide (INH) Pretreatment With Misoprostol Versus Misoprostol Alone in Missed Abortion

Adjuvant Isonicotinic Acid Hydrazide (INH) Pretreatment With Misoprostol for Induction of Abortion in First-trimester Missed Miscarriage: A Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04500002
Enrollment
240
Registered
2020-08-05
Start date
2020-09-01
Completion date
2021-07-30
Last updated
2020-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IUCD Complication

Brief summary

The primary endpoint was the success rate of adjuvant isonicotinic acid hydrazide (INH) and misoprostol versus misoprostol alone for medical termination of first-trimester pregnancy.

Detailed description

According to the American college of obstetricians and gynecologists (2005), medical abortion is an acceptable alternative for surgical procedures in pregnant women with gestational age of less than 10 weeks based on the last menstrual period Oral or vaginal misoprostol causes complete abortion in almost 85% of cases within seven days before the 12th week Adjuvant isonicotinic acid hydrazide (INH) administration with misoprostol raises the rate of complete abortion

Interventions

total dose 900 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion

DRUGMisoprostol

Misoprosrol 800mcg will be given to all patients for induction of abortion

Sponsors

Aswan University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

double blind randomized parallel assign controlled trial

Intervention model description

double blind randomized parallel assign controlled trial

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Gestational age less than 70 days gestation (\<10 wks) * Hemoglobin \>10 g/dL. * BMI between 18.5 kg/m2 and 30 kg/m2. * Missed abortion

Exclusion criteria

* Molar pregnancy. * Fibroid uterus. * Uterine anomalies. * Coagulopathy. * Medical disorder that contraindicate induction of abortion (e.g. heart failure). * Previous attempts for induction of abortion in the current pregnancy. * Allergy to misoprostol or letrozole. * Scared uterus (previous myomectomy, cesarean section, hysterectomy and ruptured uterus).

Design outcomes

Primary

MeasureTime frameDescription
number of patients with complete abortion12 hoursnumber of patients with complete abortion
time from induction to abortion12 hourstime from induction to abortion

Secondary

MeasureTime frameDescription
number of the women will undergo dilatation and curettage after failed medical induction of abortion12 hoursnumber of the women will undergo dilatation and curettage after failed medical induction of abortion

Countries

Egypt

Contacts

Primary Contacthany f Sallam, md
hany.farouk@aswu.edu.eg+20102435461
Backup Contactnahla waer Shady
hanygyne@yahoo.com+201022336052

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026